Anavex Life Sciences
Update in progressAVXL (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Anavex Life Sciences Corp. is a biopharmaceutical company focused on developing treatments for central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease dementia, Rett syndrome, schizophrenia, neurodevelopmental and neurodegenerative diseases, rare diseases, pain, and certain cancers. Its lead candidate, ANAVEX 2-73 (blarcamesine), has completed multiple Alzheimer’s trials and studied Parkinson’s and Rett, and targets SIGMAR1 and muscarinic receptors. A second candidate, ANAVEX 3-71, targets SIGMAR1 and M1 receptors and shows disease-modifying activity in AD mouse models. Founded in 2004, it is based in New York.
Company score
- Sentiment
- 0.49
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.34
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.30
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!